Treatment News : Activists Call for Earlier Access to Hep C Treatments

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » June 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

June 16, 2011

Activists Call for Earlier Access to Hep C Treatments

Hepatitis and HIV activists have called for pharmaceutical companies and drug regulators to provide earlier access to new hepatitis C virus (HCV) therapies in development to people at greater need of treatment, including people on transplant wait lists and those coinfected with HCV and HIV. These demands were issued following a meeting of 50 activists, researchers, regulators and pharmaceutical representatives held in early June in Sitges, Spain.

The recent approval of Incivek (telaprevir) and Victrelis (boceprevir) has ushered in a new era of treatment for people with HCV. Whereas people infected with the hard-to-treat strains of HCV (genotypes 1 and 4) had previously achieved cures about half the time, the addition of these new drugs to standard HCV therapy has increased cure rates by up to 50 percent and shortened the duration treatment for many.

The future also looks bright, with several drugs active against HCV in the pipeline, several of which are currently in Phase II studies. Unfortunately, however, companies have been relatively slow to provide early access to new treatments—such as compassionate use programs providing drug to those who don’t qualify for clinical trials—for those who desperately need novel therapies, such as those with advanced cirrhosis and those undergoing liver transplants. Researching the drugs in people with these conditions and in people coinfected with HIV and HCV has also been slow, according to activists.

For several years now, key stakeholders have been meeting in Sitges each year to discuss issues that hindered the development of and access to new HCV therapies for people in greatest need of more options. At this year’s meeting, early access to new treatments was at the top of the agenda.

“Meeting participants emphasized the need for early access for ‘difficult-to-treat’ populations, including patients with HIV/HCV coinfection or liver cirrhosis, people who have undergone liver transplantation or are currently on transplant waiting lists, people in marginalized groups such as drug users, and particularly, access to interferon-free regimens for people who need them,” explained representatives from one of the meeting’s key sponsors—the European Community Advisory Board (ECAB).

“The most urgent need,” the group continued, “is for people with advanced disease who have no other treatment options and cannot wait for full approval of new therapies.”

Though there was agreement at the meeting about the need to move more quickly in these populations, activists insisted that more effort is needed by companies to conduct studies sooner in the drug development process so that people in greatest need may gain earlier access to the drugs.

“It is critical to study pharmacokinetics, safety and efficacy in a wide-range of groups that will use these drugs in real world practice,” stated ECAB. “New [direct acting hepatitis drugs] must be evaluated for drug-drug interactions with HIV antiretroviral agents, opiate substitution therapy (methadone and buprenorphine), immunosuppressants, antidepressants and other medications commonly used by people with hepatitis C.”

ECAB also insisted that researchers and companies share data about these kinds of drug interactions early and to involve activists in decision making and safety monitoring throughout.

Search: Hepatitis C virus, HCV, hep C, genotype 1, genotype 4, Incivek, telaprevir, Victrelis, boceprevir, ECAB, European Community Advisory Board, expanded access, early access, cirrhosis, Sitges, Spain


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    guycmh328
    Columbus
    Ohio


    slimcuteguy
    Asheville
    North Carolina


    Fred9774
    Brooklyn
    New York


    jap022964
    el dorado
    Arkansas
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.